Provectus Biopharmaceuticals Inc's Comment on Supply Chain
The company has developed a proprietary, patented, commercial-scale process to synthesize pharmaceutical-grade rose bengal sodium (RBS) into an active pharmaceutical ingredient (API) for commercial use. Their manufacturing processes adhere to Quality-by-Design principles, current Good Manufacturing Practice (cGMP) regulations, and International Council for Harmonisation (ICH) guidelines, ensuring the elimination of impurities present in non-pharmaceutical grades of rose bengal. The company's API and drug candidate manufacturing processes and data have been reviewed and accepted by multiple national drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), Germany’s Federal Institute for Drugs and Medical Devices (BfArM), Australia’s Therapeutic Goods Administration (TGA), France’s National Agency for the Safety of Medicines and Health Products (ANSM), Italy’s Medicines Agency (AIFA), Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS), and Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT). The pharmaceutical-grade RBS name was approved by the World Health Organization (WHO) Expert Advisory Panel and included in the International Nonproprietary Names (INN) Recommended List 88 in 2022. Commercial-grade rose bengal is available from specialty chemical suppliers in the U.S. and worldwide but is manufactured under non-cGMP conditions.
Provectus Biopharmaceuticals Inc's Comment on Supply Chain
The company has developed a proprietary, patented, commercial-scale process to synthesize pharmaceutical-grade rose bengal sodium (RBS) into an active pharmaceutical ingredient (API) for commercial use. Their manufacturing processes adhere to Quality-by-Design principles, current Good Manufacturing Practice (cGMP) regulations, and International Council for Harmonisation (ICH) guidelines, ensuring the elimination of impurities present in non-pharmaceutical grades of rose bengal. The company's API and drug candidate manufacturing processes and data have been reviewed and accepted by multiple national drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), Germany’s Federal Institute for Drugs and Medical Devices (BfArM), Australia’s Therapeutic Goods Administration (TGA), France’s National Agency for the Safety of Medicines and Health Products (ANSM), Italy’s Medicines Agency (AIFA), Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS), and Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT). The pharmaceutical-grade RBS name was approved by the World Health Organization (WHO) Expert Advisory Panel and included in the International Nonproprietary Names (INN) Recommended List 88 in 2022. Commercial-grade rose bengal is available from specialty chemical suppliers in the U.S. and worldwide but is manufactured under non-cGMP conditions.
Sources:
Provectus Biopharmaceuticals Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Provectus Biopharmaceuticals Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
